Setterwalls has advised Oncopeptides AB (publ) in connection with its IPO on Nasdaq Stockholm. ABG Sundal Collier AB and Carnegie Investment Bank AB (publ) were Joint Global Coordinators and Joint Bookrunners. DNB Markets, a part of DNB Bank ASA, Sweden Branch, was Joint Bookrunner.
The offering, which was over-subscribed several times, comprised 14,130,434 shares, corresponding to approximately 36.4 percent of the total number of shares in the company after the offering. The company has also granted the Joint Global Coordinators an over-allotment option to purchase up to 2,119,565 additional shares in the offering. The total value of the offering amounts to approximately SEK 650 million and, assuming that the over-allotment option is exercised in full, the total value of the offering amounts to approximately SEK 747 million. The market value of Oncopeptides amounts to approximately SEK 1,786 million upon completion of the offering and, assuming that the over-allotment option is exercised in full, the market value of Oncopeptides amounts to approximately SEK 1,884 million.
Oncopeptides is a research and development stage pharmaceutical company developing drugs for treatment of cancer. Since the founding of the company in 2000, the company has focused primarily on the development of the product candidate Ygalo, an innovative peptidase-potentiated alkylator intended for effective and focused treatment of blood-based cancer diseases, and in particular multiple myeloma. Ygalo is intended to demonstrate better results from treatment compared to established alternative drugs in the treatment of patients with multiple myeloma. Ygalo could potentially provide treating physicians with a new treatment option for patients suffering from this severe cancer disease.